Immunome

Immunome

Immunome - Novel Immunotherapies for Cancer. Learn more

Launch date
Employees
Market cap
€872m
Enterprise valuation
€621m (Public information from Sep 2024)
Upper Merion Township Pennsylvania (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues---14.0m8.5m1.3m19.4m
% growth----(40 %)(84 %)1352 %
EBITDA(12.3m)(24.7m)(36.3m)52.8m(254m)--
% EBITDA margin---377 %(3000 %)--
Profit(17.8m)(24.7m)(36.9m)(107m)(235m)(184m)(215m)
% profit margin---(762 %)(2773 %)(13773 %)(1110 %)
EV / revenue---32.6x107.7x683.9x47.1x
EV / EBITDA-8.3x-6.3x-0.7x8.7x-3.6x--
R&D budget7.5m14.1m23.3m23.1m---
R&D % of revenue---165 %---
  • Edit
DateInvestorsAmountRound

N/A

Debt
N/A

N/A

Seed

$445k

Early VC
N/A

N/A

Seed
N/A

$735k

Debt

$467k

Debt

$200k

Debt

$7.2m

Series A
N/A

N/A

Series A
N/A

$9.3m

Early VC

$11.0m

Early VC
N/A

N/A

IPO
N/A

$17.6m

Grant
*

$125m

Private Placement VC
*
N/A

$200m

Post IPO Equity
Total Funding€155m

Recent News about Immunome

Edit
More about Immunomeinfo icon
Edit

Immunome is a biotechnology company focused on developing first-in-class therapeutics by harnessing the power of the immune system. The company operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. Immunome's proprietary discovery platform identifies novel therapeutic antibodies and their targets by analyzing the immune systems of patients who have successfully fought off diseases. This approach aims to create groundbreaking treatments for various conditions. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potential future sales of approved therapies. Immunome's team includes experts in clinical oncology and medical research, ensuring a strong foundation for scientific innovation.

Keywords: biotechnology, therapeutics, immune system, antibodies, biopharmaceutical, healthcare, medical research, discovery platform, oncology, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Immunome

Edit
Morphimmune
ACQUISITION by Immunome Jun 2023